Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


Antidiabetic agent
ALX-270-432-G005 5 g 38.00 USD
Do you need bulk/larger quantities?
Metformin is an antidiabetic agent. Reduces the cardiovascular complications of diabetes. Does not induce hypoglycemia. Inhibits hepatic gluconeogenesis via activation of the LKB1/AMPK pathway. Has antiproliferative effects in cancer cell lines.

Product Specification

Alternative Name:1,1-Dimethylbiguanide . hydrochloride
Formula:C4H11N5 . HCl
MI:14: 5938
Purity:≥97% (Assay)
Appearance:White crystalline powder.
Solubility:Soluble in water (50mg/ml).
Long Term Storage:+4°C
Use/Stability:Stock solutions are stable for up to 6 months when stored at -20°C.
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy: I.P. Yang, et al.; Ther. Adv. Med. Oncol. 11, 1758835919866964 (2019), Abstract; Full Text
Effect of human umbilical cord blood-derived mononuclear cells on diabetic nephropathy in rats: N.E. El-Ashmawy, et al.; Biomed. Pharmacother. 97, 1040 (2018), Abstract;
Metformin normalizes the structural changes in glycogen preceding prediabetes in mice overexpressing neuropeptide Y in noradrenergic neurons: L. Ailanen, et al.; Pharmacol. Res. Perspect. 6, e00389 (2018), Abstract; Full Text
H19 lncRNA alters methylation and expression of Hnf4a in the liver of metformin-exposed fetuses: J. Deng, et al.; Cell Death Dis. 8, e3175 (2017), Abstract; Full Text
Metformin alters DNA methylation genome-wide via the H19/SAHH axis: T. Zhong, et al.; Oncogene 36, 2345 (2017), Application(s): Cell culture, ARK2 and MCF-7 cells , Abstract;
Activation of the cAMP-PKA pathway antagonizes metformin suppression of hepatic glucose production: L. He, et al.; J. Biol. Chem. 291, 10562 (2016), Application(s): Cell culture, Abstract; Full Text
Compound C inhibits in vitro angiogenesis and ameliorates thrombin-induced endothelial barrier failure: D. Gündüz, et al.; Eur. J. Pharmacol. 768, 165 (2015), Application(s): Cell culture , Abstract;
Dehydroepiandrosterone activates AMP kinase and regulates GLUT4 and PGC-1α expression in C2C12 myotubes: T. Yokokawa, et al.; Biochem. Biophys. Res. Commun. 463, 42 (2015), Application(s): Cell Culture, Abstract;
Inhibition of integrin-linked kinase expression by emodin through crosstalk of AMPKα and ERK1/2 signaling and reciprocal interplay of Sp1 and c-Jun: Q. Tang, et al.; Cell Signal. 27, 1469 (2015), Application(s): Cell Culture, Abstract;
Long-Term Pancreatic Beta Cell Exposure to High Levels of Glucose but Not Palmitate Induces DNA Methylation within the Insulin Gene Promoter and Represses Transcriptional Activity: K. Ishikawa, et al.; PLoS One 10, e0115350 (2015), Application(s): Cell Culture, Abstract; Full Text
Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5: P.W. Caton, et al.; J. Endocrinol. 205, 97 (2010), Abstract;
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth: Y.H. Feng, et al.; J. Cell. Mol. Med. 15, 825 (2010), Abstract;
AMP-activated protein kinase in metabolic control and insulin signaling: M.C. Towler & D.G. Hardie; Circ. Res. 100, 328 (2007), Abstract;
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review: A. Natali and E. Ferrannini; Diabetologia 49, 434 (2006), Abstract;
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats: T. Misugi, et al.; Gynecol. Obstet. Invest. 61, 208 (2006), Abstract;
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells: M. Zakikhani, et al.; Cancer Res. 66, 10269 (2006), Abstract;
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin: R.J. Shaw, et al.; Science 310, 5754 (2005), Abstract;
Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin: C. Kilo, et al.; J. Diabetes Complications 17, 307 (2003), Abstract;
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group: Lancet 352, 854 (1998), Abstract;

Product Toolbox


Certificate of Analysis


By catalog section:


Technical Service
Customer Service

Recommend this page

Keep in touch

©2021 Enzo Life Sciences, Inc.,